<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36260265</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2509-2723</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>GeroScience</Title><ISOAbbreviation>Geroscience</ISOAbbreviation></Journal><ArticleTitle>Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus.</ArticleTitle><Pagination><StartPage>707</StartPage><EndPage>717</EndPage><MedlinePgn>707-717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11357-022-00672-7</ELocationID><Abstract><AbstractText>For more than 20 years, the World Health Organization Western Pacific Region (WPR) has been polio-free. However, two current challenges are still polio-related. First, around half of poliomyelitis elderly survivors suffer late poliomyelitis sequelae with a substantial impact on daily activities and quality of life, experiencing varying degrees of residual weakness as they age. The post-polio syndrome as well as accelerated aging may be involved. Second, after the worldwide Sabin oral poliovirus (OPV) vaccination, the recent reappearance of strains of vaccine-derived poliovirus (VDPV) circulating in the environment is worrisome and able to persistent person-to-person transmission. Such VDPV strains exhibit atypical genetic characteristics and reversed neurovirulence that can cause paralysis similarly to wild poliovirus, posing a significant obstacle to the elimination of polio. Immunization is essential for preventing paralysis in those who are exposed to the poliovirus. Stress the necessity of maintaining high vaccination rates because declining immunity increases the likelihood of reemergence. If mankind wants to eradicate polio in the near future, measures to raise immunization rates and living conditions in poorer nations are needed, along with strict observation. New oral polio vaccine candidates offer a promissory tool for this goal.</AbstractText><CopyrightInformation>© 2022. The Author(s), under exclusive licence to American Aging Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quarleri</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5110-8773</Identifier><AffiliationInfo><Affiliation>Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. quarleri@fmed.uba.ar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consejo de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina. quarleri@fmed.uba.ar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Geroscience</MedlineTA><NlmUniqueID>101686284</NlmUniqueID><ISSNLinking>2509-2723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aging</Keyword><Keyword MajorTopicYN="N">OPV</Keyword><Keyword MajorTopicYN="N">Poliomyelitis</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword><Keyword MajorTopicYN="N">Post-polio syndrome</Keyword><Keyword MajorTopicYN="N">Vaccine-derived poliovirus</Keyword></KeywordList><CoiStatement>The author declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36260265</ArticleId><ArticleId IdType="pmc">PMC9886775</ArticleId><ArticleId IdType="doi">10.1007/s11357-022-00672-7</ArticleId><ArticleId IdType="pii">10.1007/s11357-022-00672-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Racaniello VR, Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A. 1981;78(8):4887–4891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC320284</ArticleId><ArticleId IdType="pubmed">6272282</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214(4523):916–919.</Citation><ArticleIdList><ArticleId IdType="pubmed">6272391</ArticleId></ArticleIdList></Reference><Reference><Citation>Agol VI. Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol. 2006;299:211–259.</Citation><ArticleIdList><ArticleId IdType="pubmed">16568901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward CD, Stokes MA, Flanegan JB. Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol. 1988;62(2):558–562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250568</ArticleId><ArticleId IdType="pubmed">2826815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JJ, Cameron CE. Poliovirus RNA-dependent RNA polymerase (3Dpol): pre-steady-state kinetic analysis of ribonucleotide incorporation in the presence of Mg2+ Biochemistry. 2004;43(18):5126–5137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2426923</ArticleId><ArticleId IdType="pubmed">15122878</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells VR, Plotch SJ, DeStefano JJ. Determination of the mutation rate of poliovirus RNA-dependent RNA polymerase. Virus Res. 2001;74(1–2):119–132.</Citation><ArticleIdList><ArticleId IdType="pubmed">11226580</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello VR. Poliovirus neurovirulence. Adv Virus Res. 1988;34:217–246.</Citation><ArticleIdList><ArticleId IdType="pubmed">2843017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985;151(3):420–436.</Citation><ArticleIdList><ArticleId IdType="pubmed">2982959</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, et al. Progress toward polio eradication - worldwide, January 2019-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1129–1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389387</ArticleId><ArticleId IdType="pubmed">34437527</ArticleId></ArticleIdList></Reference><Reference><Citation>Chard AN, et al. Progress toward polio eradication - worldwide, January 2018-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):784–789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316320</ArticleId><ArticleId IdType="pubmed">32584798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachlin A, et al. Progress toward polio eradication - worldwide, January 2020-April 2022. MMWR Morb Mortal Wkly Rep. 2022;71(19):650–655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson AL, et al. Surveillance to track progress toward polio eradication - worldwide, 2020–2021. MMWR Morb Mortal Wkly Rep. 2022;71(15):538–544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020859</ArticleId><ArticleId IdType="pubmed">35421079</ArticleId></ArticleIdList></Reference><Reference><Citation>Malnou CE, et al. Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context. J Biol Chem. 2004;279(11):10261–10269.</Citation><ArticleIdList><ArticleId IdType="pubmed">14672927</ArticleId></ArticleIdList></Reference><Reference><Citation>Svitkin YV, Maslova SV, Agol VI. The genomes of attenuated and virulent poliovirus strains differ in their in vitro translation efficiencies. Virology. 1985;147(2):243–252.</Citation><ArticleIdList><ArticleId IdType="pubmed">3000069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochs K, et al. Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J Virol. 2003;77(1):115–122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140626</ArticleId><ArticleId IdType="pubmed">12477816</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzino BC, et al. Molecular mechanism of poliovirus Sabin vaccine strain attenuation. J Biol Chem. 2018;293(40):15471–15482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6177584</ArticleId><ArticleId IdType="pubmed">30126841</ArticleId></ArticleIdList></Reference><Reference><Citation>de Breyne S, et al. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc Natl Acad Sci U S A. 2009;106(23):9197–9202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695064</ArticleId><ArticleId IdType="pubmed">19470487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellen CU, et al. A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein. Proc Natl Acad Sci U S A. 1993;90(16):7642–7646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47198</ArticleId><ArticleId IdType="pubmed">8395052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt SL, Jackson RJ. Polypyrimidine-tract binding protein (PTB) is necessary, but not sufficient, for efficient internal initiation of translation of human rhinovirus-2 RNA. RNA. 1999;5(3):344–359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369764</ArticleId><ArticleId IdType="pubmed">10094304</ArticleId></ArticleIdList></Reference><Reference><Citation>Meerovitch K, et al. La autoantigen enhances and corrects aberrant translation of poliovirus RNA in reticulocyte lysate. J Virol. 1993;67(7):3798–3807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237744</ArticleId><ArticleId IdType="pubmed">8389906</ArticleId></ArticleIdList></Reference><Reference><Citation>Blyn LB, et al. Requirement of poly(rC) binding protein 2 for translation of poliovirus RNA. J Virol. 1997;71(8):6243–6246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191892</ArticleId><ArticleId IdType="pubmed">9223526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellen CU, et al. The cellular polypeptide p57 (pyrimidine tract-binding protein) binds to multiple sites in the poliovirus 5' nontranslated region. J Virol. 1994;68(2):941–950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC236532</ArticleId><ArticleId IdType="pubmed">8289396</ArticleId></ArticleIdList></Reference><Reference><Citation>Kafasla P, et al. Polypyrimidine tract-binding protein stimulates the poliovirus IRES by modulating eIF4G binding. EMBO J. 2010;29(21):3710–3722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982756</ArticleId><ArticleId IdType="pubmed">20859255</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrop GD, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989;63(3):1338–1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247831</ArticleId><ArticleId IdType="pubmed">2536836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura N, et al. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989;63(3):1302–1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247827</ArticleId><ArticleId IdType="pubmed">2536835</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss EG, O'Neill RE, Racaniello VR. Mapping of attenuating sequences of an avirulent poliovirus type 2 strain. J Virol. 1989;63(5):1884–1890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250599</ArticleId><ArticleId IdType="pubmed">2539491</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest S, et al. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol. 2004;78(20):11097–11107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521805</ArticleId><ArticleId IdType="pubmed">15452230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004;113(12):1743–1753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420511</ArticleId><ArticleId IdType="pubmed">15199409</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77(8):4827–4835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152153</ArticleId><ArticleId IdType="pubmed">12663789</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, et al. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J Infect Dis. 2002;186(5):585–592.</Citation><ArticleIdList><ArticleId IdType="pubmed">12195344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez H, et al. Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up. J Neuroinflammation. 2012;9:167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464723</ArticleId><ArticleId IdType="pubmed">22776106</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard S, et al. Restriction of poliovirus RNA replication in persistently infected nerve cells. J Gen Virol. 2002;83(Pt 5):1087–1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">11961263</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj A, et al. Post-poliomyelitis syndrome as a possible viral disease. Int J Infect Dis. 2015;35:107–116.</Citation><ArticleIdList><ArticleId IdType="pubmed">25939306</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol. 2012;93(Pt 3):457–474.</Citation><ArticleIdList><ArticleId IdType="pubmed">22128250</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor RI, et al. Mucosal immunity to poliovirus. Mucosal Immunol. 2022;15(1):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8732262</ArticleId><ArticleId IdType="pubmed">34239028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, et al. Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination. J Infect Dis. 2014;209(10):1628–1634.</Citation><ArticleIdList><ArticleId IdType="pubmed">24459191</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022;55(5):800–818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257994</ArticleId><ArticleId IdType="pubmed">35545029</ArticleId></ArticleIdList></Reference><Reference><Citation>Herremans TM, et al. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol. 1999;162(8):5011–5018.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202050</ArticleId></ArticleIdList></Reference><Reference><Citation>Resik S, et al. Does simultaneous administration of bivalent (types 1 and 3) oral poliovirus vaccine and inactivated poliovirus vaccine induce mucosal cross-immunity to poliovirus type 2? Clin Infect Dis. 2018;67(suppl_1):S51–S56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6206124</ArticleId><ArticleId IdType="pubmed">30376088</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217(3):371–380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5853416</ArticleId><ArticleId IdType="pubmed">29304199</ArticleId></ArticleIdList></Reference><Reference><Citation>Valtanen S, et al. Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis. 2000;182(1):1–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10882574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377–1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5611465</ArticleId><ArticleId IdType="pubmed">27638357</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, et al. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infect Dis. 2019;19(10):1121–1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">31350192</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, et al. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205(10):1554–1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">22448007</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickley EB, et al. Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden. BMJ Glob Health. 2019;4(4):e001613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730592</ArticleId><ArticleId IdType="pubmed">31543993</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbink F, et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis. 2005;191(6):990–999.</Citation><ArticleIdList><ArticleId IdType="pubmed">15717277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S, Kiyono H, Fujihashi K. Mucosal immunosenescence in the gastrointestinal tract: a mini-review. Gerontology. 2015;61(4):336–342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4475504</ArticleId><ArticleId IdType="pubmed">25531743</ArticleId></ArticleIdList></Reference><Reference><Citation>Larocca AMV, Bianchi FP, Bozzi A, Tafuri S, Stefanizzi P, Germinario CA. Long-term immunogenicity of inactivated and oral polio vaccines: An Italian retrospective cohort study. Vaccines (Basel). 2022;10(8):1329. 10.3390/vaccines10081329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9413249</ArticleId><ArticleId IdType="pubmed">36016217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch X. Post-polio syndrome recognised by European parliament. Lancet Neurol. 2004;3(1):4.</Citation><ArticleIdList><ArticleId IdType="pubmed">14700053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragonese P, et al. Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors. J Neurol Sci. 2005;236(1–2):31–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">16014307</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiner Z, et al. Risk factors for functional deterioration in a cohort with late effects of poliomyelitis: a ten-year follow-up study. NeuroRehabilitation. 2021;49(3):491–499.</Citation><ArticleIdList><ArticleId IdType="pubmed">34542042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay L, et al. Neurological symptoms in danes with a history of poliomyelitis: lifelong follow-up of late symptoms, their association with initial symptoms of polio, and presence of postpolio syndrome. Eur Neurol. 2018;80(5–6):295–303.</Citation><ArticleIdList><ArticleId IdType="pubmed">30836354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo JK, Robinson LR. Postpolio syndrome and the late effects of poliomyelitis. Part 1. pathogenesis, biomechanical considerations, diagnosis, and investigations. Muscle Nerve. 2018;58(6):751–759.</Citation><ArticleIdList><ArticleId IdType="pubmed">29752819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JH, Lin HC. Comorbidity profile of poliomyelitis survivors in a Chinese population: a population-based study. J Neurol. 2011;258(6):1026–1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">21279517</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen NM, et al. Long-term mortality after poliomyelitis. Epidemiology. 2003;14(3):355–360.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen NM, et al. Cancer risk in a cohort of polio patients. Int J Cancer. 2001;92(4):605–608.</Citation><ArticleIdList><ArticleId IdType="pubmed">11304698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin MC, et al. Pulmonary function and spinal characteristics: their relationships in persons with idiopathic and postpoliomyelitic scoliosis. Arch Phys Med Rehabil. 2001;82(3):335–341.</Citation><ArticleIdList><ArticleId IdType="pubmed">11245755</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz I, et al. The association between post-polio symptoms as measured by the index of post-polio sequelae and self-reported functional status. J Neurol Sci. 2014;345(1–2):87–91.</Citation><ArticleIdList><ArticleId IdType="pubmed">25096475</ArticleId></ArticleIdList></Reference><Reference><Citation>Amtmann D, et al. Symptom profiles in individuals aging with post-polio syndrome. J Am Geriatr Soc. 2013;61(10):1813–1815.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117294</ArticleId></ArticleIdList></Reference><Reference><Citation>Oluwasanmi OJ, et al. Postpolio syndrome: a review of lived experiences of patients. Int J Appl Basic Med Res. 2019;9(3):129–134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6652271</ArticleId><ArticleId IdType="pubmed">31392174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendebourg MJ, et al. Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome. Eur J Neurol. 2022;29(5):1435–1445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310958</ArticleId><ArticleId IdType="pubmed">35102676</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogardh C, Lexell J and Hammarlund CS. The influence of walking limitations on daily life: a mixed-methods study of 14 persons with late effects of polio. Int J Environ Res Public Health, 2022;19(13).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9265635</ArticleId><ArticleId IdType="pubmed">35805815</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogardh C, Lexell J, and Hammarlund CS. Fall-related activity avoidance among persons with late effects of polio and its influence on daily life: a mixed-methods study. Int J Environ Res Public Health, 2021;18(13).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295840</ArticleId><ArticleId IdType="pubmed">34281139</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkowane BM, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;257(10):1335–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3029445</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587–635.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cann AJ, et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984;12(20):7787–7792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC320200</ArticleId><ArticleId IdType="pubmed">6093054</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DM, et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 1985;314(6011):548–550.</Citation><ArticleIdList><ArticleId IdType="pubmed">2986004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, et al. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol. 1981;56(Pt 2):337–347.</Citation><ArticleIdList><ArticleId IdType="pubmed">6273502</ArticleId></ArticleIdList></Reference><Reference><Citation>Foiadelli T, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4903009</ArticleId><ArticleId IdType="pubmed">27287521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapusinszky B, et al. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbiol. 2010;58(2):211–217.</Citation><ArticleIdList><ArticleId IdType="pubmed">19863665</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez CV, et al. Shedding of sabin poliovirus type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine. J Infect Dis. 2004;190(2):409–416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15216480</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, et al. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235–1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5529169</ArticleId><ArticleId IdType="pubmed">25600519</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(49):1691–1699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019-February 2020. MMWR Morb Mortal Wkly Rep. 2020;69(16):489–495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2018-June 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1024–1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon J, et al. Polio endgame: the global switch from tOPV to bOPV. Expert Rev Vaccines. 2016;15(6):693–708.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751187</ArticleId></ArticleIdList></Reference><Reference><Citation>Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, Tallis G. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2022:S0264-410X(22)00277-8. 10.1016/j.vaccine.2022.03.013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10973941</ArticleId><ArticleId IdType="pubmed">35339308</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake IM, et al. Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine. N Engl J Med. 2018;379(9):834–845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985919</ArticleId><ArticleId IdType="pubmed">30157398</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, et al. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749–762.</Citation><ArticleIdList><ArticleId IdType="pubmed">25597843</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetsuriani N, et al. Responding to a cVDPV1 outbreak in Ukraine: implications, challenges and opportunities. Vaccine. 2017;35(36):4769–4776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10465089</ArticleId><ArticleId IdType="pubmed">28528761</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qassimi MA, et al. Circulating vaccine derived polio virus type 1 outbreak, Saadah governorate, Yemen, 2020. BMC Infect Dis. 2022;22(1):414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9052627</ArticleId><ArticleId IdType="pubmed">35488227</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(33):1065–1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Poliovirus is detected in sewage from north and east London. BMJ. 2022;377:o1546.</Citation><ArticleIdList><ArticleId IdType="pubmed">35738666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill M, Bandyopadhyay AS, Pollard AJ. Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use. Lancet. 2022;400(10354):713–715.</Citation><ArticleIdList><ArticleId IdType="pubmed">35988575</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam AJ, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80(17):8653–8663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh MT, et al. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27(5):736–751.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. NPJ Vaccines. 2021;6(1):94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8322168</ArticleId><ArticleId IdType="pubmed">34326330</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Llorens X, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397(10268):27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahid R, et al. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022;7(1):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837630</ArticleId><ArticleId IdType="pubmed">35149714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>